3716 Stock Overview
Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cenra Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$38.50 |
| 52 Week High | NT$44.55 |
| 52 Week Low | NT$37.00 |
| Beta | 0 |
| 11 Month Change | -0.65% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3716 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.7% | 0.4% | 2.3% |
| 1Y | n/a | 15.5% | 41.0% |
Return vs Industry: Insufficient data to determine how 3716 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 3716 performed against the TW Market.
Price Volatility
| 3716 volatility | |
|---|---|
| 3716 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in TW Market | 9.2% |
| 10% least volatile stocks in TW Market | 3.0% |
Stable Share Price: 3716 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: Insufficient data to determine 3716's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | n/a | Hou-Kai Wang | www.ccpc.com.tw |
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It offers active pharmaceutical ingredients, generic drugs for human use, over to the counter drugs, health care products for the prevention of diseases and self-care, home care and cosmetics, and animal healthcare products. The company also research and development, contracting manufacturing and international business, sale and distribution of pharmaceutical brands, and senior care services.
Cenra Inc. Fundamentals Summary
| 3716 fundamental statistics | |
|---|---|
| Market cap | NT$5.74b |
| Earnings (TTM) | NT$355.20m |
| Revenue (TTM) | NT$8.87b |
16.2x
P/E Ratio0.6x
P/S RatioIs 3716 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3716 income statement (TTM) | |
|---|---|
| Revenue | NT$8.87b |
| Cost of Revenue | NT$5.61b |
| Gross Profit | NT$3.26b |
| Other Expenses | NT$2.91b |
| Earnings | NT$355.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 36.79% |
| Net Profit Margin | 4.00% |
| Debt/Equity Ratio | 36.9% |
How did 3716 perform over the long term?
See historical performance and comparison